We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Our portfolio includes three programs in development all of which are in, or preparing to, enter Phase 2 clinical studies: NCX 470 for glaucoma, NCX 4251 for blepharitis and NCX 4280 for morning ocular congestion. Our pipeline also includes future generation stand alone NO donors in the research stage and other exploratory novel NO donating compounds targeting ophthalmic conditions. We have two ophthalmology assets approved by the U.S. FDA; VYZULTA exclusively licensed worldwide to Bausch + Lomb and commercialized in the U.S. since December 2017 as well as ZERVIATE exclusively licensed in the U.S. to Eyevance with a commercial launch in the U.S planned for spring 2019